GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Gross Profit

Adimmune (TPE:4142) Gross Profit : NT$448 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Adimmune Gross Profit?

Adimmune's gross profit for the three months ended in Dec. 2024 was NT$113 Mil. Adimmune's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was NT$448 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Adimmune's gross profit for the three months ended in Dec. 2024 was NT$113 Mil. Adimmune's Revenue for the three months ended in Dec. 2024 was NT$545 Mil. Therefore, Adimmune's Gross Margin % for the quarter that ended in Dec. 2024 was 20.75%.

Adimmune had a gross margin of 20.75% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Adimmune was 39.58%. The lowest was -99.89%. And the median was 17.96%.


Adimmune Gross Profit Historical Data

The historical data trend for Adimmune's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adimmune Gross Profit Chart

Adimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 623.06 616.86 891.08 410.94 448.06

Adimmune Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.26 -70.31 -35.00 440.27 113.10

Competitive Comparison of Adimmune's Gross Profit

For the Biotechnology subindustry, Adimmune's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's Gross Profit distribution charts can be found below:

* The bar in red indicates where Adimmune's Gross Profit falls into.


;
;

Adimmune Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Adimmune's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=1556.989 - 1108.928
=448

Adimmune's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=545.069 - 431.969
=113

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$448 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Adimmune's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=113 / 545.069
=20.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Adimmune  (TPE:4142) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Adimmune had a gross margin of 20.75% for the quarter that ended in Dec. 2024 => Competition eroding margins


Adimmune Gross Profit Related Terms

Thank you for viewing the detailed overview of Adimmune's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Adimmune Business Description

Traded in Other Exchanges
N/A
Address
Tanxing Road, No. 3, Sector 1, Tanzi District, Taichung, TWN, 427003
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.

Adimmune Headlines

No Headlines